Evaluation of galectin-3 and intestinal fatty acid binding protein as serum biomarkers in autosomal recessive polycystic kidney disease,Journal of Nephrology

当前位置： X-MOL 学术 › J. Nephrol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evaluation of galectin-3 and intestinal fatty acid binding protein as serum biomarkers in autosomal recessive polycystic kidney disease
Journal of Nephrology ( IF 2.7 ) Pub Date : 2022-08-18 , DOI: 10.1007/s40620-022-01416-8
Lindsay T Fleischer ₁ , Lance Ballester ₂ , Mohini Dutt ₃ , Kathryn Howarth ₃ , Laura Poznick ₄ , Kassa Darge _{4,

5} , Susan L Furth _{3,

6} , Erum A Hartung _{3,

6}

Affiliation

Background

Autosomal recessive polycystic kidney disease (ARPKD) causes fibrocystic kidney disease, congenital hepatic fibrosis, and portal hypertension. Serum galectin-3 (Gal-3) and intestinal fatty acid binding protein (I-FABP) are potential biomarkers of kidney fibrosis and portal hypertension, respectively. We examined whether serum Gal-3 associates with kidney disease severity and serum I-FABP associates with liver disease severity in ARPKD.

Methods

Cross-sectional study of 29 participants with ARPKD (0.2–21 years old) and presence of native kidneys (Gal-3 analyses, n = 18) and/or native livers (I-FABP analyses, n = 21). Serum Gal-3 and I-FABP were analyzed using enzyme linked immunosorbent assay. Kidney disease severity variables included estimated glomerular filtration rate (eGFR) and height-adjusted total kidney volume (htTKV). Liver disease severity was characterized using ultrasound elastography to measure liver fibrosis, and spleen length and platelet count as markers of portal hypertension. Simple and multivariable linear regression examined associations between Gal-3 and kidney disease severity (adjusted for liver disease severity) and between I-FABP and liver disease severity (adjusted for eGFR).

Results

Serum Gal-3 was negatively associated with eGFR; 1 standard deviation (SD) lower eGFR was associated with 0.795 SD higher Gal-3 level (95% CI − 1.116, − 0.473; p < 0.001). This association remained significant when adjusted for liver disease severity. Serum Gal-3 was not associated with htTKV in adjusted analyses. Overall I-FABP levels were elevated, but there were no linear associations between I-FABP and liver disease severity in unadjusted or adjusted models.

Conclusions

Serum Gal-3 is associated with eGFR in ARPKD, suggesting its value as a possible novel biomarker of kidney disease severity. We found no associations between serum I-FABP and ARPKD liver disease severity despite overall elevated I-FABP levels.

Graphical abstract

中文翻译：

半乳糖凝集素-3 和肠道脂肪酸结合蛋白作为常染色体隐性遗传性多囊肾病血清生物标志物的评价

背景

常染色体隐性遗传性多囊肾病（ARPKD）可引起纤维囊性肾病、先天性肝纤维化和门静脉高压症。血清半乳糖凝集素-3 （Gal-3）和肠道脂肪酸结合蛋白（I-FABP）分别是肾纤维化和门静脉高压症的潜在生物标志物。我们检查了 ARPKD 患者血清 Gal-3 是否与肾脏疾病严重程度相关，血清 I-FABP 是否与肝病严重程度相关。

方法

对 29 名患有 ARPKD （0.2-21 岁）且存在自体肾脏（Gal-3 分析，n = 18）和/或自体肝脏（I-FABP 分析，n = 21）的参与者进行的横断面研究。使用酶联免疫吸附测定法分析血清 Gal-3 和 I-FABP。肾脏疾病严重程度变量包括估计肾小球滤过率（eGFR）和身高调整后的总肾脏体积（htTKV）。使用超声弹性成像测量肝纤维化，测量脾长和血小板计数作为门静脉高压标志物，表征肝病严重程度。简单和多变量线性回归检查 Gal-3 与肾脏疾病严重程度（根据肝病严重程度调整）和 I-FABP 与肝病严重程度（根据 eGFR 调整）之间的关联。

结果

血清 Gal-3 与 eGFR 呈负相关;eGFR 降低 1 个标准差（SD）与 Gal-3 水平高 0.795 SD 相关（95% CI - 1.116，-0.473;p < 0.001）。当调整肝病严重程度时，这种关联仍然显著。在调整后的分析中，血清 Gal-3 与 htTKV 无关。总体 I-FABP 水平升高，但在未调整或调整的模型中，I-FABP 与肝病严重程度之间没有线性关联。